COM-902 is under clinical development by Compugen and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC). According to GlobalData, Phase I drugs for Head And Neck Squamous Cell Carcinoma (HNSC) have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how COM-902’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
COM-902 overview
COM-902 is under development for the treatment of multiple myeloma and solid tumors including head and neck squamous cell carcinoma, non-small cell lung cancer, metastatic colorectal cancer, epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer. It is administered intravenously. The drug candidate is a high affinity (femtomolar) monoclonal antibody which acts by targeting TIGIT/PVRIG. TIGIT is an immune checkpoint protein in the B7/CD28 family.
Compugen overview
Compugen is a clinical-stage drug discovery and development company that develops medicines for immuno-oncology and autoimmune diseases. The company’s pipeline comprises COM701 and PVRIG, BAY 1905254, COM902, and TIGIT. Its drug development process includes target discovery, target validation and predictive discovery programs. Compugen drug programs finds therapies to treat metastatic microsatellite stable colorectal cancer, platinum resistant ovarian cancer, advanced and metastatic non-small cell lung cancer (NSCLC) and metastatic gastric cancer. It operates in Israel, the US and Canada. Compugen is headquartered in Holon, Tel Aviv, Israel.
For a complete picture of COM-902’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
